OraSure pushes HIV test
This article was originally published in The Tan Sheet
Executive SummaryOraSure Technologies continues to seek FDA approval of its OraQuick HIV OTC over-the-counter test based on feedback from a closed-door FDA advisory panel session, the firm says Nov. 18. During a Nov. 17 meeting of FDA's Blood Products Advisory Committee to discuss over-the-counter, home-use HIV test kits, the panel met privately with OraSure to review the results of ongoing clinical studies for its OTC test, and discuss what additional clinical data FDA needs for approval. The firm already markets the OraQuick Advance rapid HIV-12 antibody test, among others
You may also be interested in...
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.